<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In an attempt to exploit bcl-2 overexpression and aberrant p53 function, two frequently encountered aberrations that predict marked treatment resistance and worse prognosis in patients with <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), we combined <z:chebi fb="1" ids="28177">theophylline</z:chebi>, pentostatin, and <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> at two dose levels (cohort I: 30 mg/m(2); cohort II: 20 mg/m(2)) on a 21-day cycle for up to six courses </plain></SENT>
<SENT sid="1" pm="."><plain>We employed a phase I/II design to determine feasibility, define the maximum tolerated dose (MTD), and explore the impact of biologic modulation on response and time to progression (<z:chebi fb="1" ids="18284">TTP</z:chebi>) in 20 patients with relapsed or <z:e sem="disease" ids="C0278791" disease_type="Neoplastic Process" abbrv="">refractory CLL</z:e> and NHL </plain></SENT>
<SENT sid="2" pm="."><plain>Eight patients were enrolled in cohort I </plain></SENT>
<SENT sid="3" pm="."><plain>They demonstrated a response rate (RR) of 28% and a 16.5-month <z:chebi fb="1" ids="18284">TTP</z:chebi> after receiving a median of two cycles </plain></SENT>
<SENT sid="4" pm="."><plain>A 50% RR was observed in this cohort when patients with adverse histologies were excluded </plain></SENT>
<SENT sid="5" pm="."><plain>Because of myelotoxicity, this dose level defined the MTD, and de-escalation occurred </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 12 patients in cohort II received 20 mg/m(2) <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>A 50% RR and an 18-month <z:chebi fb="1" ids="18284">TTP</z:chebi> were observed after a median of 5.5 cycles </plain></SENT>
<SENT sid="8" pm="."><plain>An RR of 47% and a complete remission (CR) of 5% were observed for the entire group, although responses and <z:chebi fb="1" ids="18284">TTP</z:chebi> varied greatly by histology </plain></SENT>
<SENT sid="9" pm="."><plain>Significant activity was observed in patients with <z:e sem="disease" ids="C0023434" disease_type="Neoplastic Process" abbrv="BCLL">B-cell CLL</z:e> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) </plain></SENT>
<SENT sid="10" pm="."><plain>RR and <z:chebi fb="1" ids="18284">TTP</z:chebi> for fludarabine-sensitive/na√Øve and fludarabine-refractory (FR) <z:e sem="disease" ids="C0023434" disease_type="Neoplastic Process" abbrv="BCLL">B-cell CLL</z:e> patients were 66 vs 25% and 20 vs 8.5 months, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Both FL patients responded (one with partial remission and one with CR), with a 22.5-monthly median <z:chebi fb="1" ids="18284">TTP</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>For responding patients, median <z:chebi fb="1" ids="18284">TTP</z:chebi> and overall survival (OS) was 21 and 69 months, respectively, compared to a median <z:chebi fb="1" ids="18284">TTP</z:chebi> of 2 months and an OS of 13.5 months for nonresponders </plain></SENT>
<SENT sid="13" pm="."><plain>The combination of pentostatin, <z:chebi fb="5" ids="28830">chlorambucil</z:chebi>, and <z:chebi fb="1" ids="28177">theophylline</z:chebi> is the active regimen in patients with FL and <z:e sem="disease" ids="C0023434" disease_type="Neoplastic Process" abbrv="BCLL">B-cell CLL</z:e> </plain></SENT>
</text></document>